Protective effects of Syringic acid on joint inflammation and damage in a rat model of rheumatoid arthritis.

Abstract

INTRODUCTION: Inflammation and joint damage are hallmarks of rheumatoid arthritis (RA), a chronic autoimmune disease. OBJECTIVES: This study investigated the anti-arthritic efficacy and mechanisms of Syringic acid (SA), a natural phenolic compound, in a Complete Freund's Adjuvant (CFA)-induced arthritis rat model. METHODS: Arthritis was induced in Wistar rats, which were then orally treated with SA (50, 100, 200 mg/kg) or prednisolone for 28 days. Paw swelling, arthritic index, body weight, motor functions, cytokine levels (Nuclear factor kappa B (NF-κB), Tumor necrosis factor alpha (TNF-α), Interleukin-6 (IL-6), Interleukin-1 beta (IL-1β)), antioxidant enzyme activities, histopathology, and radiological changes were assessed. Molecular docking studies were also performed. RESULTS: SA significantly reduced paw swelling and arthritic index, improved body weight and motor functions, and modulated inflammatory cytokines (NF-κB, TNF-α, IL-6, IL-1β) and oxidative stress markers dose-dependently. Histopathological and radiological analyses confirmed SA's protective effects on joint integrity. Docking studies showed strong binding affinities of SA to NF-κB and TNF-α. SA exhibits significant anti-inflammatory and anti-arthritic properties in CFA-induced RA, modulating cytokine pathways and reducing oxidative stress. CONCLUSION: These findings suggest SA's potential as a therapeutic agent for RA, warranting further clinical investigation. Key Points • Syringic acid (SA) modulated key pro-inflammatory cytokines (NF-κB, TNF-α, IL-6, IL-1β) and enhanced antioxidant enzyme activities. • Molecular docking demonstrated strong binding of SA with NF-κB and TNF-α, supporting its immunomodulatory role. • The findings highlight SA's potential as a natural immunomodulator for RA, warranting further clinical exploration.